Epcam Antagonists Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

Single User License:

EpCAM Antagonists Market - Global

Industry Analysis, Size, Share,

Growth, Trends And Forecast 2015 2023

USD 4315.5









Transparency Market Research

State Tower,

90, State Street, Suite 700.

Albany, NY 12207

United States

www.transparencymarketresearch.com

sales@transparencymarketresearch.com

Flat 10% Discount!!

Free Customization as per your requirement

You will get Custom Report at Syndicated Report

price

Report will be delivered with in 15-20 working days

Request Sample

Buy Now

REPORT DESCRIPTION

EpCAM stands for epithelial cell adhesion molecule which is a cell surface protein (antigen) and is highly expressed

in major cancer types such as breast, prostate, colon, ovarian, gastric, lung and pancreatic cancer. It is thus

considered as a well established marker for cancer of epithelial origin and an ideal therapeutic target. It is not only

limited to epithelial carcinomas but can also be expressed in various other epithelial tissues, progenitor and stem

cells. EpCAM is not found in non-epithelial cells or in cancer without epithelial origin. EpCAM plays significant role

during cell adhesion, proliferation, cell signaling, migration and differentiation. Over expression of EpCAM has been

shown to promote the proliferation in primary breast carcinomas (PBCs) and other cancer types.

Browse Full Report with TOC @ http://www.transparencymarketresearch.com/epcam-antagonists-market.html

EpCAM is usually expressed in embryonic epithelia in human and mouse; however the levels typically go down as

cells attain terminal differentiation. Catumaxomab and edrecolomab are major antibodies which are designed to bind

with epithelial cell adhesion molecules. Catumaxomab, a hybrid monoclonal antibody of rat-mouse is marketed

under the brand name Removab. Catumaxomab, developed by Fresenius Biotech and Trion Pharma GmbH, is used to

treat malignant ascites in patient with metastasizing tumor by binding against antigens EpCAM and CD3.

Edrecolomab which...